Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 M3L6OWFxd3C2b4Ppd{BCe3OjeR?= MXqzNE85OC9zNUCvNlUxKG6P M3f5Z|I1NzR6L{eyJIg> M2TiU4lv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=> NY[3bXpwOjV6OEK1OVA>
MV411 NWnV[mpUSXCxcITvd4l{KEG|c3H5 NX;PW2JCOzBxOECvNVUxNzJ3MDDuUS=> M2Dyd|I1NzR6L{eyJIg> NXLXOXhqcW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{ MnfsNlU5QDJ3NUC=
MGC-803 MnvZR4VtdCCYaXHibYxqfHliQYPzZZk> NYfGdVBvOC5zLUGwNFAhdk1? NILXcFA4OiCq NGDxVolqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYLR[YhpOjV3OUC4NFU>
SGC-7901 MoHHR4VtdCCYaXHibYxqfHliQYPzZZk> NF76XoUxNjFvMUCwNEBvVQ>? MXK3NkBp M4\lZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MX2yOVU6ODhyNR?=
MKN-28 MoPWR4VtdCCYaXHibYxqfHliQYPzZZk> NVjsOIozOC5zLUGwNFAhdk1? M3PvTFczKGh? NXXBO|BucW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3fNPVI2PTlyOEC1
MGC-803 M4DzVWZ2dmO2aX;uJGF{e2G7 NFvy[WExNjFvMUCwNEBvVQ>? MmHSNlQhcA>? NU\nW2FGcW6mdXPld{BIOi:PIHPlcIwu[3mlbHWgZZJz\XO2 MYGyOVU6ODhyNR?=
HCT-116 MlvMSpVv[3Srb36gRZN{[Xl? NV7FWVBoPTCwTR?= Mor4NlQhcA>? NWDRc5BmTE2VTx?= MWPpcoR2[2WmIFewM2cyKGG{cnXzeC=> MmrhNlUzOTB5OUS=
HT-29 NUnIPHF6TnWwY4Tpc44hSXO|YYm= NFTaVlA2OG6P M2D1VFI1KGh? M4DnVWROW09? M1TVZ4lv\HWlZXSgS|AwTzFiYYLy[ZN1 Mle0NlUzOTB5OUS=
SCC25 M1GwRWN6fG:6aXPpeJkhSXO|YYm= MlzUNVAwPTBibl2= M1;nOFI1KGh? MWDk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= M3fCdVI2OjB3NEOw
FUDA MXjDfZRwgGmlaYT5JGF{e2G7 MnHtNVAwPTBibl2= NWjFSoVUOjRiaB?= MXHk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= NIHTZoIzPTJyNUSzNC=>
Detroit562 MX;DfZRwgGmlaYT5JGF{e2G7 M13uO|ExNzVyIH7N NVPwUVlWOjRiaB?= M3\UV4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NIDicm4zPTJyNUSzNC=>
CAL27 MoruR5l1d3irY3n0fUBCe3OjeR?= MWWxNE82OCCwTR?= M3vSU|I1KGh? NGftPHdl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> NXKxOYdpOjV{MEW0N|A>
DSH1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v0NGlEPTB;NjDuUS=> MVuyOFc5PDh|OR?=
SW-1710 NFPaZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZibl2= NGT4ZWozPDd6NEizPS=>
T24 NF7S[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLMelZKSzVyPUegcm0> MofvNlQ4QDR6M{m=
RT112 NWrhclRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnOUJFKSzVyPUmgcm0> MU[yOFc5PDh|OR?=
639-V NWfBNGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uzN2lEPTB;MUCgcm0> M1rtdVI1Pzh2OEO5
SCaBER NYTDcZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDlTWM2OD1zMDDuUS=> NYX0eo1NOjR5OES4N|k>
BFTC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF5IH7N NEfxZ5EzPDd6NEizPS=>
J82 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLzdGpNUUN3ME2xPEBvVQ>? NY\aT4tKOjR5OES4N|k>
HT-1376 NGfT[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPl[4NKSzVyPUKxJI5O NUPPWIZ4OjR5OES4N|k>
647-V MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q5ZWlEPTB;Mkegcm0> MVmyOFc5PDh|OR?=
UM-UC3 NYXkdFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D1XmlEPTB;M{Ogcm0> NXS0fG9ZOjR5OES4N|k>
LB831-BLC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvxVY9JUUN3ME2zOEBvVQ>? MWOyOFc5PDh|OR?=
KU-19-19 NFTzNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjrdGp{UUN3ME2zOkBvVQ>? NUnle3luOjR5OES4N|k>
35612 NWLYbotuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN6IH7N M1PxO|I1Pzh2OEO5
5637 M3rQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jXUWlEPTB;NESgcm0> MlfTNlQ4QDR6M{m=
HT-1197 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHtU3pnUUN3ME21N{BvVQ>? NUH1fJhMOjR5OES4N|k>
MGH-U3 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTV|IH7N NI\iPW4zPDd6NEizPS=>
TCCSUP Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHLTWM2OD1zNEKgcm0> MVKyOFc5PDh|OR?=
RT4 NIDNdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj1cphpUUN3ME2xO|M{KG6P NYXuZZh3OjR5OES4N|k>
SW780 NIf5bm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN2NUGgcm0> MVeyOFc5PDh|OR?=
RKO M1ru[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17wO2lEPTB;NDDuUS=> Ml\xNlQ3QDJ5NEe=
LS-411 N M3nBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[2[mM1UUN3ME21JI5O NI\wZnUzPDZ6Mke0Oy=>
SW620 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvFWGxKSzVyPUigcm0> MW[yOFY5Ojd2Nx?=
HCT-15 M2LGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17FUGlEPTB;ODDuUS=> Mlv3NlQ3QDJ5NEe=
HuTu-80 NFPqZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnUPXRRUUN3ME2xN{BvVQ>? MYeyOFY5Ojd2Nx?=
HCT 116 NIq2dXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v5VmlEPTB;MUSgcm0> M{fQXlI1Pjh{N{S3
COLO-205 NGOwbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSyTWM2OD1zNDDuUS=> NYrFbpJrOjR4OEK3OFc>
NCI-H747 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZWmlEPTB;MUegcm0> MofnNlQ3QDJ5NEe=
COLO-678 NUG3eZE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TvZmlEPTB;MkGgcm0> MkDqNlQ3QDJ5NEe=
LoVo NGn6cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\VSG1KSzVyPUKyJI5O MX:yOFY5Ojd2Nx?=
LS-1034 M1jP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\aTWM2OD1|MTDuUS=> MYCyOFY5Ojd2Nx?=
SNU-C2B NWnPVXdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HVOWlEPTB;NEWgcm0> NGLmR2QzPDZ6Mke0Oy=>
LS-123 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\6dYRKSzVyPUezJI5O MnLwNlQ3QDJ5NEe=
SK-CO-1 NWPqb2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[wTWM2OD16MTDuUS=> M3zz[lI1Pjh{N{S3
HCC2998 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnnN21XUUN3ME2xNlghdk1? MXKyOFY5Ojd2Nx?=
MDA-MB-231 MYHGeY5kfGmxbjDBd5NigQ>? M2G5VVExOCCwTR?= NETi[2Q{OCCvaX6= MV3pcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>? M1\GPFI1OjR6Mk[1
MDA-MB-435 MWXGeY5kfGmxbjDBd5NigQ>? M3;aelExOCCwTR?= NVTy[HBIOzBibXnu NIDte2xqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= MYSyOFI1QDJ4NR?=
BT-20  M{fTfWZ2dmO2aX;uJGF{e2G7 NITufnUyODBxMkWwJI5O M3\KUlI1KGh? Ml;5doV{fWy2ZXSgbY4h[SCmb4PlMYRmeGWwZHXueEBl\XO2YXLpcIl7[XSrb36gc4YhTUeIUjygTWdHNUmULDDNSXQtKGGwZDDDVmFH NWPmW5NwOjRzN{O1OFE>
MDA-MB-231 NVP2XIMyTnWwY4Tpc44hSXO|YYm= NGW2PZAyODBibl2= MXSyOEBp NGnZUohqdmirYnn0d{B1cGVibXnndoF1d3K7IHHu[EBqdn[jc3n2[UBk[XCjY3n0feKh MYeyOFE4OzV2MR?=
H82 M3i1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f5WmlEPTB;M{CuNlchdk1? M{e3[FI1OTZ4NUC1
GLC4 NYfCboZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnSTWM2OD1{MD60O{BvVQ>? NEX6V4QzPDF4NkWwOS=>
H69 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHtZ4tkUUN3ME24N{4{PiCwTR?= M3L3e|I1OTZ4NUC1
H128 NX7IbWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rOemlEPTB;NkmuOVUhdk1? M3O1NVI1OTZ4NUC1
H146 NI[xPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDtXFdvUUN3ME2yPE42OSCwTR?= NFvES5IzPDF4NkWwOS=>
H187 NWOzfYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nOeWlEPTB;MkSuPVkhdk1? MXeyOFE3PjVyNR?=
H526 NEj4OFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4faemlEPTB;MkGuOlQhdk1? MVuyOFE3PjVyNR?=
N592 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF2LkGyJI5O M3PPeVI1OTZ4NUC1
H620 NUjiS2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rCZWlEPTB;M{KuOlchdk1? MnvZNlQyPjZ3MEW=
H792 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1TWM2OD12NT6wO{BvVQ>? M1nsRlI1OTZ4NUC1
H1173 NEK4N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF{Lk[yJI5O MoHUNlQyPjZ3MEW=
AC3 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6xXFdqUUN3ME2yOU46KG6P NGTw[lUzPDF4NkWwOS=>
H82 MkjvSpVv[3Srb36gRZN{[Xl? NIjTdZU{OCCwTR?= NGi0Zow4OiCq MmXnbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0 Mnf3NlQyPjZ3MEW=
GLC4 MlvuSpVv[3Srb36gRZN{[Xl? M3LBbVMxKG6P M4DHWlczKGh? NW\VclNZcW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 MkPJNlQyPjZ3MEW=
H146  MX;GeY5kfGmxbjDBd5NigQ>? MWCzNEBvVQ>? Mo\lO|IhcA>? MWPpcoR2[2W|IIDldpNqe3SnboSgS|IwVSCyaHHz[UBienKnc4S= MnXnNlQyPjZ3MEW=
OVCAR-5 MmHXR4VtdCCYaXHibYxqfHliQYPzZZk> MX:wMVExODBibl2= NWjCcpMzPzJiaB?= MWDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXfmOVF1OjN7MECxN|Y>
OVCAR-8 NVuycGZNS2WubDDWbYFjcWyrdImgRZN{[Xl? MX6wMVExODBibl2= Mn\MO|IhcA>? NYLQXYRUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MlfaNlM6ODBzM{[=
A1847 M1[wS2NmdGxiVnnhZoltcXS7IFHzd4F6 MYKwMVExODBibl2= NXv0cHp2PzJiaB?= NF7nSYxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NUnCU|ZIOjN7MECxN|Y>
SKOV-3 NWHDSYJlS2WubDDWbYFjcWyrdImgRZN{[Xl? MlX2NE0yODByIH7N NXu4cZVMPzJiaB?= MlrqbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MluzNlM6ODBzM{[=
OVCAR-5 NEnV[oxCeG:ydH;zbZMhSXO|YYm= MXuxNE0yODBibl2= NUPzXopROjRxNEivO|IhcA>? MWPpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfGy7 NIrDWlYzOzlyMEGzOi=>
OVCAR-8 M3jRfGFxd3C2b4Ppd{BCe3OjeR?= MofxNVAuOTByIH7N NFq4bVIzPC92OD:3NkBp Mo\2bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= NGrtTWgzOzlyMEGzOi=>
A1847 NHXDNlFCeG:ydH;zbZMhSXO|YYm= M4\SRlExNTFyMDDuUS=> NX;FT3VLOjRxNEivO|IhcA>? NVyyb4FCcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> MUWyN|kxODF|Nh?=
H2228 NYDyTXpzS2WubDDWbYFjcWyrdImgRZN{[Xl? MWiwMVExODBibl2= MWq3NkBp NEfBTY5KSzVyPUGzJI5O M4fpeVI{PTN|Mk[1
H3122 M4fqb2NmdGxiVnnhZoltcXS7IFHzd4F6 NYrkXoZOOC1zMECwJI5O NWH0Vmd4PzJiaB?= MnfVTWM2OD1zMDDuUS=> Mk\VNlM2OzN{NkW=
K008 MnrhR4VtdCCYaXHibYxqfHliQYPzZZk> MUPJR|UxRTZyIH7N M121dlI{PDF6NUKz
K028 NWnxUXJRS2WubDDWbYFjcWyrdImgRZN{[Xl? NHHUS5BKSzVyPUi0JI5O MV[yN|QyQDV{Mx?=
K029 M4nTXmNmdGxiVnnhZoltcXS7IFHzd4F6 NYDDfoRJUUN3ME20OkBvVQ>? M3KybVI{PDF6NUKz
M23 Mmq1R4VtdCCYaXHibYxqfHliQYPzZZk> MV7JR|UxRTN5LkWgcm0> NHLveowzOzRzOEWyNy=>
K033 NGTFfGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWDNSpFTUUN3ME23OU42KG6P M{C1PVI{PDF6NUKz
K008 MVTGeY5kfGmxbjDBd5NigQ>? MUmyOVAhdk1? NVrG[Zp3OjRiaB?= MkHKbY5lfWOnczDHNkBienKnc4S= NU[zS5Q5OjN2MUi1NlM>
K028 M3fXc2Z2dmO2aX;uJGF{e2G7 MYOyOVAhdk1? MoC1NlQhcA>? M3HLT4lv\HWlZYOgS|Ih[XK{ZYP0 NX;HVGplOjN2MUi1NlM>
K029 NEH2TXpHfW6ldHnvckBCe3OjeR?= NHPQXZUzPTBibl2= MmnzNlQhcA>? NGDBV2RqdmS3Y3XzJGcyKGG{cnXzeC=> Mk\uNlM1OTh3MkO=
M23 NHLOeFBHfW6ldHnvckBCe3OjeR?= MV[yOVAhdk1? MXeyOEBp MVXpcoR2[2W|IFexJIFv\CCJMj;NJIFzemW|dB?= MlXZNlM1OTh3MkO=
K033 MYrGeY5kfGmxbjDBd5NigQ>? M4Xmb|I2OCCwTR?= M1vIZlI1KGh? NUX3fYM2cW6mdXPld{BiKG2xZHXzeEBqdmO{ZXHz[UBqdiCJMTDwc5B2dGG2aX;u MlfqNlM1OTh3MkO=
K008 MWjBdI9xfG:|aYOgRZN{[Xl? MoW0NVAxKG6P MmnhO|IhcA>? MYDzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ NHviOFMzOzRzOEWyNy=>
K028 NHe3VnBCeG:ydH;zbZMhSXO|YYm= MUWxNFAhdk1? NUPQ[lJSPzJiaB?= NH;HZo1{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NIe3NnYzOzRzOEWyNy=>
K029 MW\BdI9xfG:|aYOgRZN{[Xl? M2D6NVExOCCwTR?= NXnFbJFCPzJiaB?= NUnMXGM1e2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= MUSyN|QyQDV{Mx?=
M23 NUHzWmFOSXCxcITvd4l{KEG|c3H5 MkXpNVAxKG6P NXLPeFFlPzJiaB?= NFXoUI1{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| M{nCWVI{PDF6NUKz
K033 MlHGRZBweHSxc3nzJGF{e2G7 MVmxNFAhdk1? M1XC[lczKGh? MUXzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ M33RXFI{PDF6NUKz
RD M4fnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn1TWM2OD16IH7N NHH6Uo0zOzNyM{e0NS=>
Rh41 NIn4WZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XRfWlEPTB;MUCuOEBvVQ>? NFr1RVEzOzNyM{e0NS=>
Rh18 M2TLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DCbmlEPTB;Nj6yJI5O NXK1bHBpOjN|MEO3OFE>
Rh30 NXe5fG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfKcXFDUUN3ME21MlYhdk1? NVzqRVJMOjN|MEO3OFE>
BT-12 NF;FN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDcGlEPTB;MUSuN{BvVQ>? MXOyN|MxOzd2MR?=
CHLA-266 M3rNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkKyTWM2OD1{Nz6xJI5O NWCzbmJjOjN|MEO3OFE>
TC-71 NUP4eoRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRwNTDuUS=> NHPvVXozOzNyM{e0NS=>
CHLA-9 NEfUNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\xTWM2OD12Lk[gcm0> Mkn6NlM{ODN5NEG=
CHLA-10 M1fYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPYXlZ1UUN3ME21Mlchdk1? NFLyeYwzOzNyM{e0NS=>
CHLA-258 NV[xV2J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fLWWlEPTB;Nj60JI5O MlT2NlM{ODN5NEG=
SJ-GBM2 NHrBZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLY[49YUUN3ME2xNk46KG6P NHTvUHUzOzNyM{e0NS=>
NB-1643 NESyW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjwd|lKSzVyPUeuOEBvVQ>? NGHlS4gzOzNyM{e0NS=>
NB-EBc1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTrdHBKSzVyPUG2Mlghdk1? M1m4[VI{OzB|N{Sx
CHLA-90 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJ{LkOgcm0> Mn35NlM{ODN5NEG=
CHLA-136 NFjzWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj1UXhvUUN3ME2yN{4zKG6P NYD3WJJ3OjN|MEO3OFE>
NALM-6 NYXOeFQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;IWVFnUUN3ME2xNU44KG6P M1jmPVI{OzB|N{Sx
COG-LL-317 NGC2NHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\QTWM2OD12LkSgcm0> NE\ZXGMzOzNyM{e0NS=>
RS4;11 NGDQeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonBTWM2OD1zMz61JI5O NH:3W3czOzNyM{e0NS=>
MOLT-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXrTWM2OD1zMD62JI5O MXSyN|MxOzd2MR?=
CCRF-CEM (1) NV\EO|F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvmTWM2OD1zMj61JI5O NV3DR4FJOjN|MEO3OFE>
CCRF-CEM (2) M3vqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjZcXhKSzVyPUeuNkBvVQ>? NEH0dWkzOzNyM{e0NS=>
Kasumi-1 NYTTSo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwODDuUS=> NY\GeGgxOjN|MEO3OFE>
Karpas-299 NEDD[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv2TWM2OD17Lk[gcm0> NIi4XXIzOzNyM{e0NS=>
Ramos-RA1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTdwNDDuUS=> NEDXco0zOzNyM{e0NS=>
LNCaP M3m5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPnTWM2OD16IH7N M13ZNVI{OTV{MEC0
VCaP NYXXO5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jGXmlEPTB;NzDuUS=> MWSyN|E2OjByNB?=
H1355 NX[3c4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVibl2= MYOyN|AyOjJ2OB?=
H157 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTdibl2= NWLmfI1[OjNyMUKyOFg>
H460 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYZVZ5UUN3ME24JI5O NVrPT|JIOjNyMUKyOFg>
IA-LM M1\QNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fnXmlEPTB;MUCgcm0> NWrEPVBZOjNyMUKyOFg>
HOP-62 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFzIH7N NGPyU4ozOzBzMkK0PC=>
H23 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzIH7N MlL0NlMxOTJ{NEi=
H2030 NHL3dWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfGTWM2OD1zMjDuUS=> M1rFcFI{ODF{MkS4
H441 Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KyUGlEPTB;MUSgcm0> M{jXO|I{ODF{MkS4
H2212 M1zNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj2TWM2OD1zNzDuUS=> MVyyN|AyOjJ2OB?=
SK-LU-1 NF3LVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2yTWM2OD1zODDuUS=> NH;TV4czOzBzMkK0PC=>
H2009 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\QfWlZUUN3ME2xPUBvVQ>? M2DYdVI{ODF{MkS4
H1792 MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPSclJKSzVyPUKwJI5O Mlu4NlMxOTJ{NEi=
COR-L23 NHTMOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTYTWM2OD1{MjDuUS=> M{XrZVI{ODF{MkS4
H727 M4OxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ6IH7N M1L3OFI{ODF{MkS4
H1734 NWrSN3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ6IH7N MV[yN|AyOjJ2OB?=
H358 M1PHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\GZ4hKSzVyPUK5JI5O M3LRflI{ODF{MkS4
A549 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2U2lEPTB;NEOgcm0> NFLnOo8zOzBzMkK0PC=>
H2122 M17BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\vNmlEPTB;NUOgcm0> MV[yN|AyOjJ2OB?=
Calu-1 NUXrcZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW4VVhKSzVyPUW4JI5O NWi3TXdPOjNyMUKyOFg>
Calu-6 NH6wbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n5T2lEPTB;NkSgcm0> M2i5c|I{ODF{MkS4
NCI-H1975 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPVPJl2PDhiaB?= MUfJR|UxRTF4IH7N NVHXbIJKOjJzNES2OlU>
NCI-H1975 NYXJUG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHRO|IhcA>? M3W4b2lEPTB;ODDuUS=> MVyyNlE1PDZ4NR?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 300+ddH2O
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 9, 2014 Phase 1
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 --
NCT02389751 Active, not recruiting Esophageal Cancer M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. April 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02272478 Recruiting Acute Myeloid Leukaemia|Myelodysplastic Syndrome Cardiff University|Cancer Research UK October 2014 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • Answer:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID